Alnylam Pharmaceuticals · 5 hours ago
Principal Associate Scientist, Biology
Cambridge, MA
Full-time
Onsite
Senior Level, Lead/Staff
$96K/yr - $143K/yr
5+ years expAlnylam Pharmaceuticals is a leader in RNAi therapeutics focused on advancing next-generation oligonucleotide-based therapeutics. The Principal Associate Scientist will design and execute complex immune assays and contribute to the evaluation of nucleic acid–based therapeutic platforms addressing significant unmet medical needs.
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Responsibilities
Design, optimize, and execute in vitro and ex vivo immune assays to assess immune modulation, including immune cell activation and suppression using primary and engineered immune cells
Perform multiparametric flow cytometry (e.g., surface markers, intracellular cytokines, phospho-flow) using platforms such as Cytek Aurora or BD LSR/FACSAria; analyze data using FlowJo, OMIQ, or equivalent tools to assess immune subsets, activation states, and biomarker expression
Develop and perform ELISA, MSD, cytokine profiling, western blot, and qRT-PCR to evaluate target engagement, gene expression, and knockdown efficiency
Maintain, expand, and functionally characterize primary immune cells and established mammalian cell lines
Analyze and interpret multi-parametric datasets (e.g., flow cytometry, cytokine panels, gene expression); summarize results in reports and present data to project teams and cross-functional stakeholders
Collaborate closely with internal platform teams, contribute to method development, assay validation, and protocol optimization/transfer across functional groups
Qualification
Required
BS or MS in Immunology, Molecular Biology, Cell Biology, or a related discipline with 8+ (BS) or 5+ (MS) years of hands-on laboratory experience in a biotech or pharmaceutical setting
Proven expertise in mammalian primary immune cell isolation, culture, and functional immune assays (e.g., T cell activation, proliferation, cytotoxicity)
Strong proficiency in flow cytometry, including high-parameter panel design, sample preparation, and data analysis; experience with cell sorting is highly desirable
Skilled in cell culture, ELISA/MSD, cytokine profiling, Western blotting, and qRT-PCR
Solid understanding of immune pathways, cell phenotyping, and immune assay readouts
Demonstrated ability to independently execute experiments, troubleshoot technical issues, and manage timelines effectively
Strong organizational skills, scientific rigor, and keen attention to detail
Excellent communication and interpersonal skills, with a collaborative mindset and ability to contribute across multidisciplinary project teams
Preferred
Familiarity with automation platforms (e.g., liquid handlers, high-throughput systems) is a plus
Benefits
Comprehensive benefits including medical, dental, and vision coverage
Life and disability insurance
A lifestyle reimbursement program
Flexible spending and health savings accounts
A 401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
H1B Sponsorship
Alnylam Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2022 (18)
2021 (19)
2020 (7)
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
Clinical Trials Arena
2026-01-16
Longevity.Technology
2026-01-14
2026-01-13
Company data provided by crunchbase